Channel Sponsor - Coding/Billing/Collections

Sponsored by National Medical Billing Services | info@nationalASCbilling.com | (636) 273-6711

CMS spent the most on these 20 Medicare Part B & Part D drugs

CMS released its Drug Spending Dashboards to provide insights into its Medicare Part B and Part D drug programs as well as Medicaid as a whole. The portal captured statistics from 2016.

Here are the 10 most expensive Medicare Part B drugs by brand name, generic name and total price.

1. Eylea/Aflibercept: $2.21 billion
2. Rituxan/Rituximab: $1.67 billion
3. Neulasta/Pegfilgrastim: $1.38 billion
4. Remicade/Infliximab: $1.34 billion
5. Avastin/Bevacizumab: $1.11 billion
6. Prolia/Denosumab: $1.09 billion
7. Lucentis/Ranibizumab: $1.04 billion
8. Herceptin/Trastuzumab: $703.57 million
9. Orencia/Abatacept: $586.53 million
10. Alimta/Pemetrexed Disodium: $511.82 million.

Here are the 10 most expensive Medicare Part D drugs by brand name, generic name and total price.

1. Harvoni/Ledipasvir & Sofosbuvir: $4.40 billion
2. Revlimid/Lenalidomide: $2.66 billion
3. Lantus Solostar/Insulin Glargine: $2.53 billion
4. Januvia/Sitagliptin Phosphate: $2.44 billion
5. Crestor/Rosuvastatin Calcium: $2.32 billion
6. Advair Diskus/Fluticasone/Salmeterol: $2.32 billion
7. Lyrica/Pregabalin: $2.10 billion
8. Xarelto/Rivaroxaban: $1.96 billion
9. Eliquis/Apixaban: $1.93 billion
10. Spiriva/Tiotropium Bromide: $1.82 billion

More articles on coding, billing and collections:
4 ASCs & outpatient facilities achieving certification and accreditation — April 2018
'This is simply wrong' — HHS Sec. Alex Azar criticizes high prices in hospitals compared to physician offices
NueHealth, Rothman Institute, Jefferson Health joint venture plans to reopen ASC, double case volume to 4k — 6 highlights

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months